Nawaz Rukhsana, Gul Saima, Amin Rafat, Huma Tanzeel, Al Mughairbi Fadwa
Department of Clinical Psychology, College of Medicine & Health Sciences, UAE University 15551 Al Ain, United Arab Emirates.
Department of Rehabilitation Science, Faculty of Pharmacy & Allied Health Sciences, Shifa Tameer e Millat University, Islamabad, Pakistan.
Heliyon. 2020 Nov 23;6(11):e05545. doi: 10.1016/j.heliyon.2020.e05545. eCollection 2020 Nov.
Mental health is the most neglected health sector in Pakistan, and the majority of citizens have limited or no access to primary and secondary psychiatric services. The incidence of schizophrenia (SCZ) has increased at an alarming rate in Pakistan, relative to that of other psychiatric disorders. While numerous studies have investigated SCZ, few have addressed the issue about the Pakistani population. In the present review, the researchers discuss current data integral to the prevalence, pathophysiology, and molecular genetics of SCZ; treatment approaches to the disease; and patient responses to drugs prescribed for SCZ in Pakistan. Most Pakistani patients exhibit poor responses to antipsychotic drugs. Based on our review, the researchers hypothesize that genetic dissimilarities between Pakistani and Western populations contribute to such poor responses. Consequently, an understanding of such genetic differences and the provision of personalized treatment may simultaneously aid in improving SCZ treatment in Pakistan.
心理健康是巴基斯坦最被忽视的卫生领域,大多数公民获得初级和二级精神科服务的机会有限或根本没有机会。与其他精神疾病相比,巴基斯坦精神分裂症(SCZ)的发病率以惊人的速度上升。虽然众多研究对精神分裂症进行了调查,但很少有研究涉及巴基斯坦人群的问题。在本综述中,研究人员讨论了与精神分裂症的患病率、病理生理学和分子遗传学相关的当前数据;该疾病的治疗方法;以及巴基斯坦精神分裂症患者对所开药物的反应。大多数巴基斯坦患者对抗精神病药物反应不佳。基于我们的综述,研究人员推测,巴基斯坦人和西方人群之间的基因差异导致了这种不佳反应。因此,了解这种基因差异并提供个性化治疗可能同时有助于改善巴基斯坦的精神分裂症治疗。